{"entity":{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","aka":[],"tldr":"SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.","summary":"SSGJ-612 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its target is HER2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07646626, plans to enrol 150 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SSGJ-612","url":"https://clinicaltrials.gov/search?intr=SSGJ-612"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["3sbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07646626"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Monoclonal antibody directed at HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ssgj-612/","neighbours":{"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/"}],"trial":[{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/"}]}}